Objective-Palmitoylation, the reversible addition of the lipid palmitate to a cysteine, can alter protein localization, stability, and function. The ZDHHC family of protein acyl transferases catalyzes palmitoylation of numerous proteins. The role of ZDHHC enzymes in intact tissue and in vivo is largely unknown. Herein, we characterize vascular functions in a mouse that expresses a nonfunctional ZDHHC21 (F233Δ). Approach and Results-Physiological studies of isolated aortae and mesenteric arteries from F233Δ mice revealed an unexpected defect in responsiveness to phenylephrine, an α1 adrenergic receptor agonist. In vivo, F233Δ mice displayed a blunted response to infusion of phenylephrine, and they were found to have elevated catecholamine levels and elevated vascular α1 adrenergic receptor gene expression. Telemetry studies showed that the F233Δ mice were tachycardic and hypotensive at baseline, consistent with diminished vascular tone. In biochemical studies, ZDHHC21 was shown to palmitoylate the α1D adrenoceptor and to interact with it in a molecular complex, thus suggesting a possible molecular mechanism by which the receptor can be regulated by ZDHHC21. Conclusions-Together, the data support a model in which ZDHHC21 F233Δ diminishes the function of vascular α1 adrenergic receptors, leading to reduced vascular tone, which manifests in vivo as hypotension and tachycardia. This is to our knowledge the first demonstration of a ZDHHC isoform affecting vascular function in vivo and identifies a novel molecular mode of regulation of vascular tone and blood pressure. The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
T he maintenance of vascular tone is of paramount importance to the health and survival of humans and other mammals. Multiple integrated signaling pathways coordinate to control vascular tone, which in turn determine blood flow distribution and blood pressure (BP) via alteration of peripheral vascular resistance. The α1 adrenergic receptor (AR) is a key determinant of vascular tone and its signaling has been the subject of intensive study over many decades. It is the target of several drugs that are used clinically to modify BP. 1 The identification of novel molecular pathways that may regulate α1 adrenergic signaling and BP is of great importance in further developing our understanding of these critical pathways and in identifying novel drug targets.
Protein thioacylation is the post-translational attachment of a lipid, generally the saturated 16 carbon palmitate, to a cysteine sidechain via a labile thioester bond. Commonly referred to as palmitoylation, this modification typically affects the function of the substrate proteins by altering trafficking, localization, and stability. 2 Unlike other lipid modifications such as prenylation or myristolylation, palmitoylation is reversible and thus may be regulated. Novel proteomic studies performed by us and others have shown that hundreds of cellular proteins in diverse tissues and cell types are palmitoylated and that palmitoylation can regulate cellular functions. [3] [4] [5] [6] The ZDHHC family enzymes, encoded by >20 genes in mice and humans, catalyze palmitoylation of substrate proteins. 7 In yeast, knockdown of ≥1 genes encoding ZDHHC isoforms attenuated palmitoylation of nearly all known palmitoylproteins, highlighting the importance of these enzymes in regulating cellular protein palmitoylation. 4 Historically, protein palmitoylation has been studied largely in biochemical or cellular assays. However, the recent identification of the ZDHHC family of proteins has allowed for in vivo studies on the role of protein palmitoylation via genetic approaches to alter enzyme expression and consequently modify cellular palmitoylprotein content. Several mouse models of ZDHHC deficiency have been generated to examine the function of this family of enzymes. For example, a mouse with a hypomorphic Zdhhc5 allele displayed evidence of defective hippocampaldependent learning, 8 whereas knockout of Zdhhc17 9 and Zdhhc13 10 each led to a phenotype that mimics Huntington disease, a progressive neurodegenerative disorder. In addition, ZDHHC enzymes have been associated with human diseases, such as schizophrenia 11 and certain cancers. 12, 13 ZDHHC21 is a protein acyl transferase known to be expressed in endothelial cells and elsewhere. 14, 15 We have previously shown that in cultured endothelial cells, ZDHHC21 supports the palmitoylation of important functional proteins including endothelial nitric oxide synthase (eNOS), 15 which produces the pleiotropic gaseous second messenger NO, and PECAM1, a cell adhesion molecule that may play a role in angiogenesis and transendothelial cell migration. 3 Others have identified additional substrates for ZDHHC21, including sex steroid receptors 16 and the nonreceptor tyrosine kinases Fyn 17 and Lck. 18 In this work, we sought to characterize the role of ZDHHC21 in vascular function in vivo. We used the depilated mouse 19 (MGI: 94884) that harbors a spontaneous mutation in the gene for ZDHHC21. The resulting mutant protein has a deletion of phenylalanine 233 (F233Δ) and lacks acyl transferase activity toward established substrates. 17 For example, ZDHHC21 F233Δ cannot palmitoylate eNOS nor Fyn in in vitro assays. Unexpectedly, we find that the F233Δ homozygous mice as well as derived cells and tissues display reduced responsiveness to α1 AR (αAR) agonists. In vivo, tachycardia and hypotension were observed in the F233Δ mice, findings consistent with reduced peripheral vascular resistance as the result of impaired vascular action of α1 AR. At the molecular level, ZDHHC21 is found to form a complex with, and to increase the palmitoylation of, α1D AR. These results suggest a molecular mechanism for the action of ZDHHC21 because palmitoylation has been shown to alter signaling and function of many related G protein-coupled receptors (GPCRs). These data are to our knowledge the first demonstration of the in vivo role of a particular protein acyl transferase in vascular function and reveal a novel mode of regulation of vascular responsiveness to α1 AR agonists. These data may pave the way to novel therapeutics that modulate vascular tone by altering protein acyl transferase activity.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
Vessels isolated from F233Δ mice display impaired responsiveness to phenylephrine, an α1 AR agonist. To evaluate vascular function in F233Δ mice, we studied aortic rings isolated from wild-type (WT) and mutant mice by wire myography (Figure 1 ). When contraction was induced by phenylephrine, an α1 AR agonist, maximal increases in tension were reduced by ≈30% in F233Δ rings relative to WT ( Figure 1A ; WT, 0.92±0.08 g; F233Δ, 0.64±0.05 g; P<0.001). Log(EC 50 ) for phenylephrine were similar (−7.0±0.3 versus −6.9±0.3). Contraction induced by a distinct receptor agonist, serotonin, was not impaired ( Figure 1B) , nor was contraction induced by high concentrations of potassium, a receptor-independent stimulus ( Figure 1C ).
In addition, endothelial-dependent relaxations were studied in response to acetylcholine. Regardless of whether vessels were preconstricted with phenylephrine or serotonin, endothelial-dependent relaxations were indistinguishable in WT and F233Δ mice ( Figure I in the online-only Data Supplement).
Because the aorta is a conduit vessel and does not contribute significantly to peripheral vascular resistance in vivo, we sought to evaluate function of the mesenteric artery. Using pressure myography in cannulated vessels, we found that high concentrations of potassium in both WT and F233Δ third order mesenteric arteries induced similar contractions (not shown). However, as in the aortae, vessels derived from F233Δ mice displayed significantly reduced maximal contraction to phenylephrine ( Figure 1D ; WT, 109±7%; F233Δ, 49±5%; P<0.0001). In addition, Log(EC 50 ) for phenylephrine in the mutant was similar to WT (WT, −5.9±0.2; F233Δ, −5.4±0.3). The above data suggest defective functioning of the α1 AR in the vascular smooth muscle cells. We have previously demonstrated expression of Zdhhc21 using quantitative polymerase chain reaction approaches in cultured endothelial cells, 3 but expression has not been documented in vascular smooth muscle. We thus performed quantitative polymerase chain reaction experiments on a variety of mouse tissues and cultured mouse cells ( Figure II in the online-only Data Supplement). Zdhhc21 transcripts were confirmed in aorta, heart, as well as cultured mouse aortic smooth muscle cells. Overall, expression was noted in all tissues tested at fairly similar levels: the highest expressing tissue was only 3-fold higher than the lowest. Similar widespread expression of Zdhhc21 has been reported elsewhere. 14
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F233Δ Mice Display Impaired Response to Infusion of Phenylephrine
To determine whether the hyporesponsiveness to phenylephrine that was observed in isolated vessels was also present in intact mice, phenylephrine was infused into WT and F233Δ mice while BP was monitored. Mice were maintained under inhaled isoflurane anesthesia while BP was measured directly via a carotid artery catheter. Preinfusion BPs were similar in WT and F233Δ mice under these conditions. Phenylephrine was infused at 30 μg/kg per minute for 15 minutes, and the steady-state BP was determined at the conclusion of the infusion period. As shown in Figure 2 , systolic blood pressure increased substantially within 2 to 3 minutes after initiation of the phenylephrine infusion. At 15 minutes, the steady-state systolic blood pressure had increased by 15.6±1.8 mm Hg in WT versus only 8.2±0.7 mm Hg in F233Δ mice (P=0.003; n=6).
F233Δ Mice Display Reduced BP and Tachycardia
The impaired response to α1 AR agonists observed in isolated vessels and in intact mice suggests that F233Δ mice might exhibit evidence of diminished peripheral vascular resistance in vivo. To explore this possibility in awake, unrestrained mice, we used a telemetry system to characterize the hemodynamics of the F233Δ and WT mice. The averaged results from data collected continuously during 72 hours showed that all the mice displayed characteristic diurnal variations in BP and heart rate (HR; Figure 3 ). The F233Δ mice were hypotensive, particularly at peak night-time hours ( Figure 3A ; Table I in the online-only Data Supplement), which in nocturnal rodents is a period of increased activity, HR, and BP. Mean arterial pressure at night was reduced in F233Δ mice relative to WT by 5.1±2.1 mm Hg (n=7, P=0.03), but was not statistically different during the day ( Figure 3A and 3B; Table I in the onlineonly Data Supplement).
The F233Δ consistently displayed increased HR relative to WT ( Figure 3G and 3H); however, the pattern was opposite that of BP in that differences were greater during the day (66±20 bpm; P=0.007) and smaller at night (49±19 bpm; P=0.02). The tachycardia was not the result of increased physical activity on the part of the F233Δ mice as measurements of activity collected using the telemetry system revealed that the F233Δ mice were less active at night than the WT mice (WT, 13.9±2.0 versus F233Δ, 5.2±0.4 arbitrary units; P=0.001).
Further analysis of relationships between HR and BP suggest that the tachycardia in the F233Δ mice served to attenuate differences in BP between the strains. For example, the differences in BP were smallest during the day, when greatest relative increase in HR in the F233Δ mice was observed ( Figure 3 ; Table I in the online-only Data Supplement). At night, the differences in BP were largest, and differences in HR were smallest. A plot of the difference in mean HR between WT and F233Δ versus the difference in mean arterial pressure ( Figure IIIA in the online-only Data Supplement) suggests that mean arterial pressure would be ≈13 mm Hg less in F233Δ mice if HRs were equivalent. The plot also reveals that when BP was similar between the strains, the HR was ≈70 bpm greater in the F233Δ mice. A plot of the same data set as mean HR versus mean mean arterial pressure for each strains clearly indicate the rightward shift of the curve in the F233Δ mice, illustrating the increased HR required to attain the same BP in this strain ( Figure IIIB in the online-only Data Supplement).
Variability in HR was assessed by determining the SD of interbeat intervals in WT and F233Δ mice. This variability may increase with increased cholinergic input. 20 Although the SD of interbeat intervals was less in F233Δ mice, the difference was not statistically significant (WT, 6.5±1.5 ms; F233Δ 4.7±1.0 ms; P=0.32; Table II in the online-only Data Supplement).
F233Δ Mice Have Elevated Catecholamine Levels and Expression of α1 AR
Because mutant mice and isolated arteries were found to be hyporesponsive to pharmacological α1 adrenergic agonist, we hypothesized that levels of endogenous expression of α1 AR and its agonists might be altered in the mutant mice. To assess this possibility, we measured catecholamine levels in overnight urine collections ( Figure 4 ). Overnight collections reflect levels present when BP differences were greatest. Both adrenaline and noradrenaline levels were found to be significantly elevated in the F233Δ mice, suggesting increased average plasma levels during this time period. Furthermore, quantitative polymerase chain reaction analysis of aortae showed that mRNA levels encoding α 1A AR was significantly increased in mutant vessels, whereas subtypes 1B and 1D were not statistically different ( Figure 4C ). In contrast, mRNA levels for contractile proteins, Myh11 and aortic smooth muscle actin, were not significantly different in F233Δ when compared with WT.
F233Δ Mice Do Not Display Evidence of Cardiac Abnormalities
The combination of hypotension and tachycardia seen in the F233Δ mice, although consistent with diminished vascular tone, might also be the result of cardiac dysfunction. To assess this possibility, we performed transthoracic echocardiography to examine cardiac structure and function. There were no significant differences in stroke volume, ejection fraction, or left ventricular volume at systole or diastole between WT and F233Δ mice (Table 1 ). Furthermore, hematoxylin and eosin-stained sections of F233Δ myocardium did not reveal any obvious abnormalities (not shown). These data together suggest that the hemodynamic phenotype does not relate to abnormal cardiac function.
F233Δ Mice Do Not Have Evidence of Abnormal Fluid Losses
The combination of tachycardia and hypotension might arise from a reduction in intravascular volume, which would contribute to reduced cardiac output by reducing preload. The normal stroke volume and left ventricular diastolic volume observed by echocardiography argues against this possibility ( Table 1) , but we nonetheless further evaluated fluid losses from skin and kidney. The F233Δ mice have abnormal skin characterized by thickened epidermis and thinned coat raising the possibility of a defect in cutaneous barrier function, although none was detected in published investigations. 17 To confirm this, we directly measured transepidermal water losses in homozygous mutant and heterozygous control mice at the age of 4 to 6 days, before the onset of hair growth which interferes with the measurements. The skin and fur of heterozygous mice are grossly indistinguishable from WT, thus water flux is the heterozygotes, which is expected to reflect that in the WT. In this assay, no significant difference between F233Δ and heterozygous mice was noted ( Figure 5 ). To evaluate whether the F233Δ mice displayed abnormal handling of salt and water, serum analyses from mice on standard chow were performed ( Table 2) . They revealed no differences in blood urea nitrogen, sodium, nor potassium, suggesting no significant differences in renal function, renal handling of water and potassium, nor in the renin-angiotensin-aldosterone pathway. Hematoxylin and eosin-stained sections of renal tissue did not reveal any obvious significant abnormalities in F233Δ mice (not shown). To further test for hemodynamically significant renal salt (and water) wasting, mice were placed on a very low salt diet (0.01%) while simultaneously monitoring hemodynamic status using a telemetry system. If the mutant mice were unable to appropriately retain sodium under conditions of dietary deprivation, they would be expected to demonstrate worsening tachycardia and hypotension associated with progressive fluid losses and intravascular depletion. However, both F233Δ and WT mice were able to tolerate the low-sodium diet for 2 weeks with 
Fibroblasts Derived From F233Δ Mice Display Reduced Responses to Phenylephrine
To further explore the mechanisms underlying the observed hyporesponsiveness to α1 AR agonism in F233Δ mice, embryonic fibroblast cell lines were derived from WT and F233Δ mice. Signaling induced by phenylephrine was assessed by activation of the ERK1/2 pathway, a common pathway activated downstream of a variety of G protein-coupled receptors. Signaling by F233Δ embryonic fibroblasts in response to phenylephrine (10 µmol/L) was markedly diminished ( Figure  6 ). At 5 minutes, the maximal increase in the ratio of phospho-ERK to total ERK relative to time 0 was 2.5±0.3 for WT versus 1.3±0.1 for F233Δ; P<0.001, n=7. However, signaling by serotonin (10 µmol/L) was no different at 5 minutes (2.6±0.2 versus 2.7±0.1; P=NS), mimicking the results observed with serotonin in isolated aortic rings. These results corroborate those obtained in intact aortic rings, and suggest that the molecular mechanism underlying this defect is preserved in cultured cells, and does not depend on the presence of differentiated smooth muscle cells nor of intact vascular tissue.
ZDHHC21 Palmitoylates and Interacts With α1D AR In Vitro
To examine the molecular basis of diminished α1 AR function in F233Δ vessels, we hypothesized that ZDHHC21 may palmitoylate key proteins involved in the α1 AR signaling pathway, and that loss of palmitoylation of those proteins might lead to disruption of α1 AR signaling in the F233Δ mouse. Several proteins involved in canonical signaling by α1ARs are known to be palmitoylated. Most class A GPCRs are palmitoylated at ≥1 cysteines in the C-terminal tail distal to the seventh (ie, last) transmembrane helix, thus creating a fourth cytoplasmic loop. 21 Palmitoylation of the α1B AR has been reported at such a position. 22 Furthermore, Gαq, the heterotrimeric G protein activated by α1 AR, is known to be palmitoylated, and to require palmitoylation for proper interaction with receptors. 22, 23 We tested for interactions between ZDHHC21 and α1D AR and Gαq using a standard coexpression strategy 24 and biosynthetic incorporation of a palmitate analog, 17-octadecynoic acid (17-ODYA), into the palmitoylproteins. 6 ODYA can be derivatized with a fluorophore using click chemistry to allow for visualization and quantitation of protein palmitoylation. 6 Because the α1D subtype mediates vascular contraction in response to phenylephrine and catecholamines, 25, 26 we assessed whether α1D AR was a substrate for ZDHHC21. As seen in Figure 7A and quantified in Figure 7B , palmitoylation of α1D AR (myc tagged) was increased ≈2.5-fold in the presence of WT ZDHHC21 (HA tagged), but not when coexpressed with either ZDHHC21 F233Δ or a mutant in which the key catalytic cysteine is mutated to serine (C120S). Of note, α1D AR was detected as 3 different bands, consistent with the presence of monomers, dimmers, and higher order aggregates. This multimerization of heterologously expressed α1 AR has been previously reported. 27 Total expression of α1D AR was increased by expression of WT, but not mutant ZDHHC21 ( Figure 7A and 7B) .
In addition to the receptor, the ability of ZDHHC21 to palmitoylate Gαq was tested, but no interaction was detected, in agreement with previously published results. 18 In contrast, both ZDHHC3 and ZDHHC7 increased Gaq palmitoylation, as previously reported 18 (Figure 7C and quantified in Figure 7D ).
As has been pointed out previously, 28 a limitation of metabolic labeling studies in the assessment of palmitoylation is that it may reflect increased steady-state palmitoylation, or merely increased turnover with either unchanged or even decreased steady-state palmitoylation. To distinguish between these possibilities, we used resin-assisted capture (known as acyl-RAC) methodology to purify palmitoylated receptors from cell lysates. 29, 30 This label-free method purifies palmitoylated proteins from a mixture Anesthetized mice were analyzed with a Vevo 2100 ultrasound system. Parameters shown were derived by tracing the images of the left ventricle at systole and diastole. F233Δ mice showed no significant difference from WT in any of the parameters shown; n=9, P>0.05 for all comparisons by unpaired 2-tailed t test. WT indicates wild-type.
in the presence (but not absence) of hydroxylamine, and thus reflects the total pool of palmitoylated protein present. Using this analysis, we found that palmitoylation of α1D AR was increased in the presence of ZDHHC21, albeit to a smaller degree that was observed using ODYA technique. These data suggest that ZDHHC21 does in fact increase steady-state palmitoylation of α1D AR, as well as total expression of α1D AR. The smaller magnitude of the effect in this assay when compared with the ODYA technique is not unexpected, as it only distinguishes between protein that is not palmitoylated at all from that with at least 1 palmitoyl group. The addition of more palmitoyl groups beyond the first will not increase signal in the RAC assay, as it could in the ODYA/click experiment ( Figure 7A ).
We additionally undertook analysis of α1A and α1B AR palmitoylation using ODYA labeling. However, extensive aggregation observed with these receptors precluded quantitative interpretation of the experiments (not shown). Aggregations seemed to be worse after immunoprecipitation, and exacerbated further by the click chemistry labeling reaction, perhaps because the use of organic solvents in the reaction We tried various detergent, buffer, and reducing conditions without satisfactory results. Experiments using the RAC technique (which is less sensitive overall but less susceptible to aggregation because of the use of SDS denaturation) failed to demonstrate increased palmitoylation of either α1A or α1B ( Figure IV in the onlineonly Data Supplement). These data do not rule out an interaction, but suggest that the effects on α1D are the most robust.
As further evidence for interaction between α1D AR and ZDHHC21 coimmunoprecipitation studies were performed. In several cases, ZDHHC enzymes have been found to coimmunoprecipitate with substrates. 15, 31 Indeed, ZDHHC21 could be shown to coimmunoprecipitate with α1D AR when coexpressed in HEK293 cells ( Figure 7G) . Unfortunately, such experiments could not be performed on native tissues owning to lack of specific antibodies for α1 AR. 32 Together, these data suggest that the ZDHHC21 could affect the function of α1 AR in vascular smooth muscle cells by directly palmitoylating the α1D receptor.
Discussion
This report documents the first demonstration that a particular ZDHHC palmitoyltransferase can regulate vascular function in vivo. Collectively, the data support a model (Figure 8 ) in which inactivation of ZDHHC21 causes reduced responses to α1 AR agonists by diminishing palmitoylation of the α1D AR, which manifests in vivo as diminished vascular tone (ie, hypotension and tachycardia). Reduced responsiveness to phenylephrine was observed in intact mice (Figure 2 ), isolated vessels (Figure 1) , as well as embryonic fibroblasts ( Figure 6) . In contrast, responses to other stimuli for vascular contraction remained intact, such as serotonin and high [K+] in both isolated aortic rings (Figure 1 ) and embryonic fibroblasts ( Figure  6 ), which suggests that the F233Δ vessels are not globally disabled. In further support of this model, in which disruption of vascular responsiveness to α1 AR plays a central role, we found increased levels of endogenous catecholamines and vascular α1 AR expression in F233Δ mice (Figure 4) .
The F233Δ mice were found to be hypotensive and tachycardic, which is consistent with diminished vascular tone. Diminished vascular tone is the expected phenotype in the setting of reduced α1 AR activity. Other explanations for the tachycardia and hypotension, such as cardiac abnormalities or loss of fluids via skin or kidney, were sought but not observed ( Figure 5 ; Table 1 ). Abnormalities of α1 AR function can clearly give rise to phenotypes similar to the one identified here for the ZDHHC21 mutant mouse. The most convincing data come from studies of α1D knockout mice, which display impaired phenylephrine-induced contraction in aortic rings, 25, 33 diminished pressor reponse to infused phenylephrine in intact mice, 25 and hypotension. 25, 33, 34 A separate study also found hypotension in α1D knockout mice relative to WT, but the difference (≈3 mm Hg) did not reach statistical significance. 35 Furthermore, 2 papers have shown that α1D knockout mice are resistant to the development of hypertension in a model using salt loading and subtotal nephrectomy. 33, 35 The reduction in BP in the F233Δ mice was relatively modest, in part because of masking by relative tachycardia ( Figure III in the online-only Data Supplement). The tachycardia may be a compensatory response to the diminished vascular tone, but it could also result from other molecular defects not identified here, such as hyperactivity of the β1 AR. Figure 5 . F233Δ mice do not lose fluid via skin. Transepidermal water losses (TEWL) were measured to determine whether fluid losses might occur via the skin, given the abnormal fur and skin in F233Δ mice. 17 TEWL in the F233Δ homozygous mice was not significantly different from that in the heterozygous mice (P=0.29 by 2-tailed t test). Blood was collected via retro-orbital bleeds from anesthetized mice and analyzed using an iStat instrument and EC8+ cartridges. Data are the mean±SEM; n=11 for each group. P values are calculated by 2-tailed unpaired Student's t test. BUN indicates blood urea nitrogen; and WT, wild-type. February 2016
The differences in BP in F233Δ mice were largest, and statistically significant, only at night. This result makes sense in light of our model, which posits a role for diminished α1 AR pressor function, in that night is the time at which catecholamine levels are highest in rodents, and thus the time at which deficiency in α1 AR signaling would be expected to be most pronounced. A similar diurnal variation in BP abnormalities was reported in the mouse knockout of the Tric-A gene, which encodes a monovalent cation channel. These mice displayed hypertension, but only during the daytime, as the high sympathetic output of night-time hours masked the effect. 36 The Guytonian model of long-term BP regulation would predict that in response to hypotension, the kidney would minimize sodium excretion so as to expand intravascular volume and normalize BP. 37 However, such renal compensation likely does not occur in the setting of vascular α1 AR dysfunction because of the involvement of the intrarenal vasculature in addition to other peripheral beds. Thus, renal blood flow is predicted to be preserved even at lower arterial BPs so that sodium retention is not triggered. Furthermore, as α1 AR expressed in renal tubular epithelial cells may be involved in promoting renal tubular sodium reabsorption, 38 its dysfunction may thwart the normal increase in tubular sodium reabsorption anticipated in the setting of hypotension. Regardless, the similarity of the phenotype between the F233Δ mice and several of the α1 AR KO mice suggests that defects in α1 AR are indeed sufficient to cause hypotension and tachycardia.
About the molecular mechanisms underlying the defect in α1 AR signaling in the F233Δ mice, our results suggest that ZDHHC21 can directly interact with and palmitoylate the α1D AR (Figure 7) , a subtype important for vasoconstriction in various vascular beds. 26, 39 The palmitoylation of α1D was specific because ZDHHC21 could not palmitoylate Gaq ( Figure 7C ). Palmitoylation of the α1A and the α1B receptors could not be demonstrated, although the data do not rule out an interaction ( Figure IV in the online-only Data Supplement). Unfortunately, direct demonstration of altered palmitoylation levels of α1D receptors in vivo is technically difficult, owing to lack of availability of a suitable antibody, 32 and low receptor expression levels.
Numerous GPCRs have been found to be regulated in different ways by palmitoylation, which affects nearly all family A receptors. Palmitoylation has been found in different studies to affect ligand binding, G protein coupling, and desensitization, although the details have varied depending on the particular receptor studied. 21, 40 In addition, complexity related to GPCR palmitoylation and its functional role may arise from the fact that many GPCRs are palmitoylated at >1 site-and different sites may have different kinetics and play different functional roles, as was recently reported it the β1 AR. 41 There are no previous reports about palmitoylation of α1D AR; however, the α1B AR was found to be palmitoylated at 2 cysteines in the C-terminal tail in a ligand-dependent fashion. 22 The significance of this palmitoylation was not determined and the catalytic enzymes(s) were not identified. 22, 23 Here, we find evidence that stability of α1D AR are affected by palmitoylation because coexpression of WT ZDHHC21 (but not the inactive mutants F233Δ or C120S) increased the expression levels ( Figure 7B and 7F ). An interrelationship between palmitoylation and protein abundance has been observed in multiple proteins, and more recently was found to be a nearly universal phenomenon in proteomic analyses of hypomorph of Zdhhc5 42 and hypomorph of Zdhhc17. 43 In both cases, nearly all proteins found to be in less abundance after purification of palmitoylproteins were also found to be in less abundance in total pools. These results, using 2 unrelated systems, suggest that palmitoylation may commonly affect protein abundance and stability.
Investigations in the area of GPCR palmitoylation have nearly all been done in vitro because creation of in vivo models of GPCRs that lack palmitoylation with traditional methods is difficult. Furthermore, manipulation of GPCR palmitoylation via genetic alteration of ZDHHC enzyme expression has not been possible owing to lack of information on ZDHHC-substrate interactions, although recent data on GPCR palmitoylation has addressed this. 44, 45 In the one in vivo study on GPCR palmitoylation published, on the photoreceptor rhodopsin, a novel phenotype was discovered involving lack of stability of the unliganded opsin that is formed after bleaching of the receptor. Functionally, this instability caused retinal degeneration after exposure to bright light. This phenotype was not previously appreciated, despite multiple studies of rhodopsin palmitoylation that had been done in vitro. The F233Δ mouse thus represents an opportunity to explore the consequences of GPCR palmitoylation in vivo using genetic approaches.
Identifying substrates of ZDHHC enzymes that mediate in vivo phenotypes has been a difficult question. 42, 43 Although several mouse models of different ZDHHC isoform mutants, hypomorphs, and knockouts have been reported, each with striking phenotypes ranging from neurodegeneration 10, 46 to osteoporosis, 47 the identification of the exact molecular mechanism (ie, the specific protein substrate in which lack of palmitoylation results in the observed phenotype) has been generally elusive. Broadly, investigators have tried unbiased proteomic approaches 42, 43 as well as more focused candidate gene approaches. The former has involved purification of palmitoyl proteins from tissues or cells of WT and mutant animals coupled with quantitative proteomic techniques. To date, relatively modest changes in the palmitoylome have been detected using these approaches, although many interesting candidates have been identified whose . ZDHHC21 palmitoylates α1D adrenergic receptor (α1D AR) but not Gαq. A, α1D AR (myc tagged) was expressed in HEK293 cells along with green fluorescent protein (GFP; control), wild-type (WT) ZDHHC21, or nonfunctional ZDHHC21 mutants (HA tagged). The degree of palmitoylation was determined by metabolic labeling with the palmitate analog 17-octadecynoic acid (ODYA), followed by immunoprecipitation of α1D AR, and click chemistry to attach a fluorophore to incorporated ODYA. The intensity of the ODYA signal was normalized to the total amount of α1D AR as determined by Western blot. The α1D AR tends to aggregate when expressed in HEK293 cells, and can be detected as monomers, dimers, and higher order aggregates at molecular weight of ≈65, ≈130, and >250 kDa. B, Quantitation of palmitoylation (ie, normalized ODYA incorporation) and total α1D AR expression; n=3, *P<0.05 compared with GFP, by 1-way ANOVA with Dunnett post test. C, ZDHHC21 does not palmitoylate Gαq, whereas ZDHHC3 does. D, Quantitation of Gαq palmitoylation; n=3, *P<0.05 compared with GFP, by 1-way ANOVA with Dunnett post test. E, ZDHHC21 increases α1D AR palmitoylation as judge by acyl-RAC methodology. Palmitoylated α1D AR is isolated in the presence, but not in the absence of hydroxylamine (H 3 NO). F, Quantitation of palmitoylation (normalized to total expression) and total expression of α1D AR; both are increased by ZDHHC21; n=5, *P<0.05 compared with GFP by 2-tailed t test. G, ZDHHC21 can be coimmunoprecipitated by α1D AR, suggesting the 2 proteins interact in a molecular complex. The data are representative of 3 experiments. Figure 8 . Proposed model of disturbed physiology in F233Δ mice. Mutation of ZDHHC21 causes decreased α1D adrenergic receptor (α1D AR) function (possibly because of reduced vascular α1D AR palmitoylation), which results in diminished peripheral vascular resistance (PVR). The reduced PVR manifests as reduced blood pressure as observed in the telemetry studies, although the reduction is mitigated by increased heart rate (Figure 3 ). relevance to observed phenotypes awaits confirmation. 42, 43 Here, we used a candidate gene approach, which has the advantage of focusing on proteins with a known role in the observed phenotype. Furthermore, this approach allows for direct investigation of proteins that may be too low in abundance to be readily detected with proteomic methods, such as GPCRs. A similar approach led to the identification of MT1-MMP as a possible substrate of ZDHHC13 that causes the osteoporosis that occurs in mice with a nonsense mutation in Zdhhc13. 48 Of course the candidate gene approach will not identify every substrate of a given ZDHHC enzyme, and available data suggest that most enzymes have multiple substrates. 4 For example, several additional substrates of ZDHHC21 have been reported, including eNOS, PECAM1, fyn, 17 and sex steroid receptors. 16 It is likely that multiple proteins are differently palmitoylated in F233Δ mice besides α1D AR. Thus, the hemodynamic phenotypes described herein may not be (solely) because of nor fully explained by the identified interaction between ZDHHC21 and α1D AR.
Of note, although previously published in vitro experiments had shown the knockdown of ZDHHC21 led to diminished palmitoylation of eNOS and reduced NO production, 15 experiments with the F233Δ mice did not show any evidence of diminished eNOS function in vivo. For example, the mice were hypotensive (Figure 3) , not hypertensive as would be expected if eNOS function were diminished. 49 Furthermore, endothelial function, as judged by acetylcholine-induced relaxations in isolated vessels (which depends on stimulated NO production), was normal ( Figure I in the online-only Data Supplement). Thus, either the eNOS effects are overwhelmed by defective palmitoylation of other proteins or eNOS is palmitoylated normally in the F233Δ mice, perhaps because of upregulation of other ZDHHC isoforms with reported activity toward eNOS. 15 In sum, this report shows for the first time that a ZDHHC protein acyl transferase enzyme, ZDHHC21, can affect vascular function in vivo, possibly by disrupting α1 AR-mediated vascular contraction. Several chemical inhibitors of both protein acyl transfersases 50, 51 and acyl protein thioesterases, 52, 53 enyzmes which catalyze palmitate removal, have been described. Thus, pharmacological manipulation of palmitoylation may soon be possible. ZDHHC21 and related family members may present novel targets for drug therapy to modulate vascular function.
